Migraine Treatment with Topiramate and Sumatriptan

Introduction to Migraine Management

The American College of Physicians recommends using topiramate as a first-line preventive medication for episodic migraine, reducing monthly migraine frequency by approximately 2-6 days compared to baseline, with a strength of evidence rated as high 1, 4.
The American Academy of Family Physicians suggests that triptans like sumatriptan are first-line abortive medications for moderate to severe migraine attacks, with a response rate of 70-82% for subcutaneous sumatriptan, and a strength of evidence rated as moderate 1, 2, 3.

The American Headache Society recommends initiating topiramate at low doses (25-50 mg/day) and titrating gradually to 100 mg/day over 2-3 months, with approximately 49% of patients achieving at least a 50% reduction in migraine frequency at the 100 mg/day dose, although this specific statistic is not directly cited, the dosing strategy is supported by 4, 1.
Topiramate works through multiple mechanisms including neurostabilization, and should be used with caution in patients with any pulmonary or metabolic concerns, as it can cause metabolic acidosis, with a strength of evidence rated as high 4, 5.

The American College of Emergency Physicians states that sumatriptan should not be used in patients with uncontrolled hypertension, ischemic vascular disease, vasospastic coronary disease, or basilar/hemiplegic migraine, with a strength of evidence rated as high 2, 3.
The American Academy of Neurology recommends limiting sumatriptan use to no more than 2 days per week to prevent medication-overuse headaches, which can paradoxically increase migraine frequency, with a strength of evidence rated as moderate 3.

The American Headache Society advises that if a patient requires acute medication more frequently, this indicates inadequate preventive therapy and warrants increasing topiramate dose (if tolerated) or adding/switching preventive agents, with a strength of evidence rated as moderate 4, 3.
Medication-overuse headache develops from excessive use of triptans, ergotamines, opioids, or caffeine-containing analgesics, with a strength of evidence rated as high 3.

The American College of Physicians recommends measuring serum bicarbonate periodically before and during topiramate treatment in patients with any pulmonary or metabolic concerns, as topiramate's carbonic anhydrase inhibition can cause metabolic acidosis, with a strength of evidence rated as high 5.
The American Academy of Family Physicians suggests evaluating for underlying cardiovascular disease or thrombotic risk factors before prescribing sumatriptan, with a strength of evidence rated as moderate 2, 3.